Vera Therapeutics VERA Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Vera Therapeutics (VERA) reported proceeds from exercises of stock options and other stock issuances of $3.94M in Q1 2026.
- How has Vera Therapeutics's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Vera Therapeutics's proceeds from exercises of stock options and other stock issuances increased by 157.1% year-over-year, from $1.53M to $3.94M.
- What is the long-term trend for Vera Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), Vera Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a 49.6% compound annual growth rate (CAGR), from $2.08M to $6.98M.